CD8A and neoplasm: In conclusion, we identified the β-catenin/Tim-3 axis as a novel mechanism that inhibits DC-mediated CD8 T cell responses, thereby supporting Tim-3 as a new target for therapeutic intervention to improve the anti-tumor efficacy of DC vaccines.